PeptiDream Inc. (4587.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 1,044.00

From 52W high−41.17%

Volume1.05M

Market capJPY 135.64B

P/E (TTM)—

P/S (TTM)7.1x

Div yield—

Key dataSep 18, 2026

Open

JPY 1,044.00

From 52W high

−41.17%

Volume

1.05M

Market cap

JPY 135.64B

ValuationView details →

P/E (Fwd)

11.4x

EV/EBITDA

−47.4x

P/E (TTM)

—

RSI (14)

52.6

MomentumView details →

1D Return

+0.72%

YTD Return

−35.41%

ValuationView details →

P/E (Fwd)

11.4x

P/E (TTM)

—

EV/EBITDA

−47.4x

EV/Sales

6.7x

P/S (TTM)

7.1x

P/B (TTM)

2.8x

ProfitabilityView details →

Gross Margin

39.48%

Net Margin

−18.74%

EBITDA Margin

−15.15%

ROE (TTM)

−7.18%

ROA (TTM)

−4.78%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

−59.19%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−11.65%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+0.72%

YTD Return

−35.41%

1Y Return

−35.33%

RSI (14)

52.6

vs 50D SMA

+4.17%

vs 200D SMA

−15.45%

Capital & dividendView details →

Debt/Equity

0.33x

Current Ratio

4.06x

Quick Ratio

3.66x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

19.05B

Net Income (TTM)

−3.57B

Op. CF (TTM)

−4.40B

Next earningsNov 5, 2026 →

Latest newsMore news →

PeptiDream announced on August 12 that it received a milestone payment from Novartis for the initiation of a Phase 1 clinical trial of a compound created through their joint research.39d ago

PeptiDream announced its IFRS results for the first half of 2026 (January-June), with a consolidated net loss of 1.99 billion yen, narrowing from a loss of 2.12 billion yen in the same period last year.39d ago

Similar companies

KAKEN PHARMACEUTICAL CO.,LTD.4521.T Mochida Pharmaceutical Co.,Ltd.4534.T GNI Group Ltd.2160.T Nxera Pharma Co.,Ltd.4565.T Oncolys BioPharma Inc.4588.T KISSEI PHARMACEUTICAL CO.,LTD.4547.T Find similar companies →

Latest newsMore news →

PeptiDream announced on August 12 that it received a milestone payment from Novartis for the initiation of a Phase 1 clinical trial of a compound created through their joint research.39d ago PeptiDream announced its IFRS results for the first half of 2026 (January-June), with a consolidated net loss of 1.99 billion yen, narrowing from a loss of 2.12 billion yen in the same period last year.39d ago PeptiDream announced plans to launch its first proprietary drug by 2032, with a Phase 1 clinical trial for a kidney cancer radiopharmaceutical candidate started in July 2026.40d ago